Vertex Pharmaceuticals Incorporated
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vertex Pharmaceuticals Incorporated sits in the top decile of US sponsors by registered trial count (#156 of 15,742 sponsors by registered trial count).
Vertex Pharmaceuticals Incorporated: 191 sponsored US clinical trials, 20 recruiting.
Vertex Pharmaceuticals Incorporated sponsors 191 registered US clinical trials on ClinicalTrials.gov, 20 of them currently recruiting, and 144 completed. 67 of these trials are in Phase 3-4 (later-stage) and 119 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cystic Fibrosis, with 20 trials.
Top-decile sponsor footprint
Vertex Pharmaceuticals Incorporated ranks in the top decile of sponsors by registered trial count (#156 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
144 of 161 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
191 total, page 4 of 4
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
NCT01511432
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
NCT01467492
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
NCT01467479
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
NCT01501383
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
NCT01459913
Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01262352
Drug-Drug Interaction Study Between Telaprevir and Buprenorphine
NCT01275599
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
NCT01216046
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
NCT01225211
Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01161537
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
NCT01080222
Rollover Study of VX-770 in Cystic Fibrosis Subjects
NCT01117012
Study of VX-985 in Subjects With Chronic Hepatitis C
NCT01144936
Study of VX-770 on Desipramine
NCT01153542
A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
NCT01052194
Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770
NCT01060566
A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults
NCT01038167
Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy
NCT01048255
Study of VX-770 and Rifampin in Healthy Male Subjects
NCT01018368
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
NCT00983853
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
NCT00953706
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
NCT00909727
Virology Follow up Study in Subjects Previously Treated With Telaprevir
NCT00916474
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation
NCT00909532
Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection
NCT00911963
Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
NCT00865904
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
NCT00758043
Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
NCT00789126
A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
NCT00627926
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
NCT00623649
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
NCT00535847
Study of Telaprevir in Subjects With Hepatic Impairment
NCT00509210
AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
NCT00493441
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
NCT00457821
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
NCT00420784
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
NCT00336479
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
NCT00273936
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
NCT00262483
A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries
NCT00500812
Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
NCT00088504
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
NCT00003847
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 62 |
| Phase 2 | 57 |
| Phase 3 | 62 |
| Phase 4 | 5 |
What is open in the Vertex Pharmaceuticals Incorporated pipeline
20 recruiting of 191 indexed (10% open); 144 completed (75%).
Phase mix: 67 late (III/IV) vs 119 early (I/II) (early-phase heavy).
Top condition: Cystic Fibrosis (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vertex Pharmaceuticals Incorporated: open-pipeline peers nationwide
Peers matched on 191 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Vertex Pharmaceuticals Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 191 trials (± recruiting share)
- Vanderbilt-Ingram Cancer Center · 189 trials · 15% recruiting
- Hospital for Special Surgery, New York · 194 trials · 18% recruiting
- Nationwide Children's Hospital · 188 trials · 15% recruiting
- Arizona State University · 187 trials · 15% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Alexion Pharmaceuticals · 10% recruiting · 162 trials
- Zimmer Biomet · 10% recruiting · 115 trials
- University of Mississippi Medical Center · 10% recruiting · 96 trials
- Bastyr University · 11% recruiting · 19 trials
Related
What to do with this Vertex Pharmaceuticals Incorporated page
191 registered trials is a research-attention snapshot, not an endorsement of Vertex Pharmaceuticals Incorporated or any single study.
- 20 of Vertex Pharmaceuticals Incorporated's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cystic Fibrosis is the condition Vertex Pharmaceuticals Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cystic Fibrosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vertex Pharmaceuticals Incorporated pipeline card: 191 registered trials from official public datasets.Report a data error.